Patrick J. Hanley

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

32h-index3.6kcitations235works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(88), Cytomegalovirus and herpesvirus research(87), Immune Cell Function and Interaction(54), Virus-based gene therapy research(49), Hematopoietic Stem Cell Transplantation(31)

Publications235 total

Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
354 Engineering tumor-associated antigen-specific T cells to resist transforming growth factor beta in the tumor microenvironment
Regular and Young Investigator Award Abstracts·2025Open Access
Mesenchymal Stromal Cells Mitigate Prolonged Cardiopulmonary Bypass-Induced Neuroinflammation
Interdisciplinary CardioVascular and Thoracic Surgery·2025Open Access
576 Third-party tumor-associated antigen-specific T cells demonstrate safety in patients with high-risk pediatric solid tumors: preliminary results from a phase I clinical trial
Regular and Young Investigator Award Abstracts·2025Open Access
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
Nature Communications·2025· 3 citedOpen Access
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy
UNC Libraries·2025Open Access
Outcome Analysis Post Virus-Specific T Cell Therapy for the Treatment of Adenoviremia in Immunocompromised Pediatric Patients
Transplantation and Cellular Therapy·2025
Clinical and Immunophenotypic Analysis of Donor-Derived T Cells Targeting Twelve Viral Antigens Administered to Patients after Hematopoietic Stem Cell Transplant
Transplantation and Cellular Therapy·2025
Abstract 4142562: Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery – MeDCaP Phase I Trial
Circulation·2024
Environmental monitoring of current good manufacturing practices cleanroom facilities for manufacturing of cellular therapy products in an academic hospital setting
Cytotherapy·2024· 2 citedOpen Access
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant
American Journal of Transplantation·2024· 24 citedOpen Access
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
Nature Communications·2024· 21 citedOpen Access
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication
Nature Communications·2024· 5 citedOpen Access
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products
Cytotherapy·2024· 2 citedOpen Access
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy
The Journal of Infectious Diseases·2024· 11 citedOpen Access
Reduced Healthcare Resource Utilization in TCR Αβ/CD19-Depleted Haploidentical Compared to Matched Related and Unrelated Donor Hematopoietic Cell Transplant in First 100 Days for Pediatric Hematologic Malignancies
Transplantation and Cellular Therapy·2024
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study
Blood Advances·2024· 10 citedOpen Access
Review of flow cytometry as a tool for cell and gene therapy
Cytotherapy·2023· 12 citedOpen Access
612 Lymphodepletion blunts the antigen-spreading response post TAA-T cell therapy for pediatric solid tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Secondary Graft Loss After Third-party "Off-The-Shelf" Antigen-Specific T cell Infusion
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
page 1 of 12Next →

Frequent Co-authors

Catherine M. Bollard(45), Carolina Colli Cruz(16), Michael D. Keller(16), Cliona M. Rooney(13), Helen E. Heslop(11), Elizabeth J. Shpall(10), Adrian P. Gee(9), Ann M. Leen(7), Hao Liu(7), Haili Lang(6), Jeremy D. Rubinstein(6), Carolyn Lutzko(6), José A. Cancelas(6), Stella M. Davies(6), Michael Grimley(6), Richard J. Simpson(6), Robert A. Krance(5), Malcolm K. Brenner(5), Fahmida Hoq(5), Thomas Leemhuis(5)